Indeed, it is probable that a considerable proportion of tumors (i. e. p16Ink4A-sporadic and p16Ink4A-focal lung neoplasms) has been clustered differently in previous works, determining a substantial heterogeneity in the reported results and therefore leading to a nihilistic and skeptical vision of p16Ink4A as a trustable biomarker in the lung. This evidence concerns the gene CDKN2A and lung neoplasm.